Modeling hepatitis C virus dynamics: Liver regeneration and critical drug efficacy

Journal of Theoretical Biology

Volumn 247, Issue 2, 2007, Pages 371-381

  Dahari, Harel ^a   Lo, Arthur ^a,b   Ribeiro, Ruy M ^a   Perelson, Alan S ^a  

^a LOS ALAMOS NATIONAL LABORATORY   (United States)

^b Entelos Inc   (United States)

Author keywords

Critical drug efficacy; Hepatitis C virus; Liver regeneration; Mathematical modeling; Viral kinetics

Indexed keywords

ALPHA INTERFERON; INTERFERON; RIBAVIRIN; VIRUS RNA;

DISEASE TREATMENT; DRUG; HEPATITIS; NUMERICAL MODEL; VIRAL DISEASE;

ARTICLE; CELL PROLIFERATION; CHRONIC HEPATITIS; DRUG EFFICACY; HALF LIFE TIME; HEPATITIS C; HEPATITIS C VIRUS; LIVER CELL; LIVER REGENERATION; MATHEMATICAL MODEL; NONHUMAN; PRIORITY JOURNAL; STEADY STATE;

ANTIVIRAL AGENTS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER REGENERATION; MODELS, BIOLOGICAL; TREATMENT OUTCOME;

HEPATITIS C VIRUS;

EID: 34249896188     PISSN: 00225193     EISSN: 10958541     Source Type: Journal    
DOI: 10.1016/j.jtbi.2007.03.006     Document Type: Article

References (27)

1. Alter M.J., Margolis H.S., Krawczynski K., Judson F.N., Mares A., Alexander W.J., Hu P.Y., Miller J.K., Gerber M.A., and Sampliner R.E. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N. Engl. J. Med. 327 27 (1992) 1899-1905
2. Bekkering F.C., Neumann A.U., Brouwer J.T., Levi-Drummer R.S., and Schalm S.W. Changes in anti-viral effectiveness of interferon after dose reduction in chronic hepatitis C patients: a case control study. BMC Gastroenterol 1 (2001) 14
3. Callaway D.S., and Perelson A.S. HIV-1 infection and low steady state viral loads. Bull. Math. Biol. 64 1 (2002) 29-64
4. Colombatto P., Civitano L., Oliveri F., Coco B., Ciccorossi P., Flichman D., Campa M., Bonino F., and Brunetto M.R. Sustained response to interferon-ribavirin combination therapy predicted by a model of hepatitis C virus dynamics using both HCV RNA and alanine aminotransferase. Antivir. Ther. 8 6 (2003) 519-530
5. Dahari H., Feliu A., Garcia-Retortillo M., Forns X., and Neumann A.U. Second hepatitis C replication compartment indicated by viral dynamics during liver transplantation. J. Hepatol. 42 4 (2005) 491-498
6. Dahari H., Major M., Zhang X., Mihalik K., Rice C.M., Perelson A.S., Feinstone S.M., and Neumann A.U. Mathematical modeling of primary hepatitis C infection: noncytolytic clearance and early blockage of virion production. Gastroenterology 128 4 (2005) 1056-1066
7. Dahari, H., Ribeiro, R.M., Perelson, A.S., 2007. Triphasic decline of HCV RNA during antiviral therapy. Hepatology, in press.
8. Dixit N.M., Layden-Almer J.E., Layden T.J., and Perelson A.S. Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 432 7019 (2004) 922-924
9. Fausto N. Liver regeneration and repair: hepatocytes, progenitor cells, and stem cells. Hepatology 39 6 (2004) 1477-1487
10. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Goncales Jr. F.L., Haussinger D., Diago M., Carosi G., Dhumeaux D., Craxi A., Lin A., Hoffman J., and Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347 13 (2002) 975-982
11. Gerlach J.T., Diepolder H.M., Zachoval R., Gruener N.H., Jung M.C., Ulsenheimer A., Schraut W.W., Schirren C.A., Waechtler M., Backmund M., and Pape G.R. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 125 1 (2003) 80-88
12. Gretch D.R., dela Rosa C., Carithers Jr. R.L., Willson R.A., Williams B., and Corey L. Assessment of hepatitis C viremia using molecular amplification technologies: correlations and clinical implications. Ann. Intern. Med. 123 5 (1995) 321-329
13. Herrmann E., Lee J.H., Marinos G., Modi M., and Zeuzem S. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 37 6 (2003) 1351-1358
14. Huang Y., Rosenkranz S.L., and Wu H. Modeling HIV dynamics and antiviral response with consideration of time-varying drug exposures, adherence and phenotypic sensitivity. Math. Biosci. 184 2 (2003) 165-186
15. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., Goodman Z.D., Koury K., Ling M., and Albrecht J.K. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358 9286 (2001) 958-965
16. Michalopoulos G.K., and DeFrances M.C. Liver regeneration. Science 276 5309 (1997) 60-66
17. Neumann A.U., Lam N.P., Dahari H., Gretch D.R., Wiley T.E., Layden T.J., and Perelson A.S. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282 5386 (1998) 103-107
18. NIH., 2002. National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002. Hepatology 36(5 Suppl 1), S3-20.
19. Pawlotsky J.M., Dahari H., Neumann A.U., Hezode C., Germanidis G., Lonjon I., Castera L., and Dhumeaux D. Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology 126 3 (2004) 703-714
20. Perelson A.S., Neumann A.U., Markowitz M., Leonard J.M., and Ho D.D. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271 5255 (1996) 1582-1586
21. Perelson A.S., Herrmann E., Micol F., and Zeuzem S. New kinetic models for the hepatitis C virus. Hepatology 42 4 (2005) 749-754
22. Powers K.A., Ribeiro R.M., Patel K., Pianko S., Nyberg L., Pockros P., Conrad A.J., McHutchison J., and Perelson A.S. Kinetics of hepatitis C virus reinfection after liver transplantation. Liver Transpl. 12 2 (2006) 207-216
23. Sentjens R.E., Weegink C.J., Beld M.G., Cooreman M.C., and Reesink H.W. Viral kinetics of hepatitis C virus RNA in patients with chronic hepatitis C treated with 18 MU of interferon alpha daily. Eur. J. Gastroenterol. Hepatol. 14 8 (2002) 833-840
24. Villano S.A., Vlahov D., Nelson K.E., Cohn S., and Thomas D.L. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology 29 3 (1999) 908-914
25. Wei X., Ghosh S.K., Taylor M.E., Johnson V.A., Emini E.A., Deutsch P., Lifson J.D., Bonhoeffer S., Nowak M.A., Hahn B.H., et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373 6510 (1995) 117-122
26. Wein L.M., D'Amato R.M., and Perelson A.S. Mathematical analysis of antiretroviral therapy aimed at HIV-1 eradication or maintenance of low viral loads. J. Theoret. Biol. 192 1 (1998) 81-98
27. World Health Organization, 2000. Hepatitis C-global prevalence (update). Weekly Epidemiol. Rec. 75, 18-19.